NPMA2 is a genetic variant that produces 16S RRNA methyrtransferase; In this way, bacteria gain full resistance to all aminoglycoside antibiotics.
It was first defined in Japan about 20 years ago and remained silent for a long time. However, recently reappeared in a hospital tests in the Netherlands.
So far, the United Kingdom has been confirmed in Germany, France, USA, China and Australia.
Emergency intervention is required, mortality rates increased by 30 percent
Professor of Complutense University. Bruno González-Zorn says that mortality rates of up to 30 percent are observed in hospital infections caused by bacteria carrying NPMA2.
The gene can easily spread through species through plasmids and mobile genetic elements in bacteria.
What to do?
Increasing molecular scanning capacity in hospitals allows to detect the spread of the gene early.
It is necessary to limit the use of antibiotics, especially in aminoglycosides according to the right and requirement.
It is imperative to accelerate R & D studies and develop new treatment strategies and anti-resistor drugs.
Experts, such as NPMA2 full resistance to the spread of genes expressing a historical threshold, because these genes and infections are resistant to existing treatment methods, they say. If such shock genes are not controlled, the mortality rates in hospitals and their effects on public health may rise to levels that give alarm.
